Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration

Selexipag, a selective prostacyclin receptor agonist, is approved for treating pulmonary arterial hypertension in WHO Group 1 adult patients. Compared to parenteral prostacyclin formulations, selexipag offers a significant improvement in patient’s and caregiver’s quality of life because of its oral...

Full description

Bibliographic Details
Main Authors: Jenna M. Faircloth, Neelam D. Bhatt, Corey A. Chartan, Ryan D. Coleman, Natalie Villafranco, Fadel E. Ruiz, Raysa Morales-Demori, Elise Whalen, Erin Ely, Rozmeen Fombin, Nidhy P. Varghese
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Pediatrics
Subjects:
pediatric pulmonary hypertension
selexipag
treprostinil
initiation
transition
prostacyclin
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2023.1050508/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2023.1050508/full

Similar Items